DRUG DISCOVERY TOXICOLOGY

FROM TARGET ASSESSMENT TO TRANSLATIONAL BIOMARKERS


1,000,000 Discovery Compounds
Lead Compound Identification
Lead Compound Optimization
Lead & Backup Drug Candidates
Nonclinical Studies
Clinical Phases
Regulatory Approval for Launch of a New Chemical Entity

EDITED BY

Yvonne Will
J. Eric McDuffie
Andrew J. Olaharski
Brandon D. Jeffy

WILEY

DRUG DISCOVERY TOXICOLOGY

DRUG DISCOVERY TOXICOLOGY

From Target Assessment to Translational Biomarkers

Edited by

YVONNE WILL
J. ERIC McDUFFIE
ANDREW J. OLAHARSKI
BRANDON D. JEFFY

WILEY

Copyright © 2016 by John Wiley & Sons, Inc. All rights reserved

Published by John Wiley & Sons, Inc., Hoboken, New Jersey
Published simultaneously in Canada

No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, recording, scanning, or otherwise, except as permitted under Section 107 or 108 of the 1976 United States Copyright Act, without either the prior written permission of the Publisher, or authorization through payment of the appropriate per-copy fee to the Copyright Clearance Center, Inc., 222 Rosewood Drive, Danvers, MA 01923, (978) 750-8400, fax (978) 750-4470, or on the web at www.copyright.com. Requests to the Publisher for permission should be addressed to the Permissions Department, John Wiley & Sons, Inc., 111 River Street, Hoboken, NJ 07030, (201) 748-6011, fax (201) 748-6008, or online at http://www.wiley.com/go/permissions.

Limit of Liability/Disclaimer of Warranty: While the publisher and author have used their best efforts in preparing this book, they make no representations or warranties with respect to the accuracy or completeness of the contents of this book and specifically disclaim any implied warranties of merchantability or fitness for a particular purpose. No warranty may be created or extended by sales representatives or written sales materials. The advice and strategies contained herein may not be suitable for your situation. You should consult with a professional where appropriate. Neither the publisher nor author shall be liable for any loss of profit or any other commercial damages, including but not limited to special, incidental, consequential, or other damages.

For general information on our other products and services or for technical support, please contact our Customer Care Department within the United States at (800) 762-2974, outside the United States at (317) 572-3993 or fax (317) 572-4002.

Wiley also publishes its books in a variety of electronic formats. Some content that appears in print may not be available in electronic formats. For more information about Wiley products, visit our web site at www.wiley.com.

Library of Congress Cataloging-in-Publication Data:

Names: Will, Yvonne, editor.
Title: Drug discovery toxicology : from target assessment to translational biomarkers / edited by Yvonne Will [and three others].
Description: Hoboken, New Jersey : John Wiley & Sons, Inc., [2016] | Includes bibliographical references and index.
Identifiers: LCCN 2015039627 (print) | LCCN 2015050089 (ebook) | ISBN 9781119053330 (cloth) | ISBN 9781119053323 (Adobe PDF) | ISBN 9781119053392 (ePub)
Subjects: LCSH: Drugs–Toxicology. | Drugs–Testing. | Toxicity testing. | High throughput screening (Drug development)
Classification: LCC RA1238 .D75 2016 (print) | LCC RA1238 (ebook) | DDC 615.9/02–dc23
LC record available at http://lccn.loc.gov/2015039627

Printed in the United States of America

10 9 8 7 6 5 4 3 2 1

CONTENTS

LIST OF CONTRIBUTORS **xxi**

FOREWORD **xxv**

PART I INTRODUCTION **1**

1 Emerging Technologies and their Role in Regulatory Review **3**
Thomas J. Colatsky

1.1 Introduction 3
1.2 Safety Assessment in Drug Development and Review 4
    1.2.1 Drug Discovery 4
    1.2.2 Preclinical Development 5
1.3 The Role of New Technologies in Regulatory Safety Assessment 6
    1.3.1 *In Silico* Models for Toxicity Prediction 6
    1.3.2 Cell-Based Assays for Toxicity Prediction 7
1.4 Conclusions 8
References 8

PART II SAFETY LEAD OPTIMIZATION STRATEGIES **13**

2 Small-Molecule Safety Lead Optimization **15**
Donna M. Dambach

2.1 Background and Objectives of Safety Lead Optimization Approaches 15
2.2 Target Safety Assessments: Evaluation of Undesired Pharmacology and Therapeutic Area Considerations 16
2.3 Implementing Lead Optimization Strategies for Small Molecules 16
    2.3.1 Strategic Approach 17
    2.3.2 Application of Prospective Models 17
    2.3.3 Application of Retrospective Models 22
2.4 Conclusions 23
References 23

3 Safety Assessment Strategies and Predictive Safety of Biopharmaceuticals and Antibody Drug Conjugates 27

Michelle J. Horner, Mary Jane Hinrichs and Nicholas Buss

3.1 Background and Objectives 27
3.2 Target Safety Assessments: Strategies to Understand Target Biology and Associated Liabilities 28
  3.2.1 Target Safety Assessment for Biopharmaceuticals Targeting the Immune System 28
3.3 Strategic Approaches for Biopharmaceuticals and ADCs 29
  3.3.1 Modality-Associated Risks 29
  3.3.2 mAbs 29
  3.3.3 ADCs 30
  3.3.4 On-Target Toxicity 30
  3.3.5 Off-Target Toxicity 32
  3.3.6 Evaluation of Novel Warheads 32
  3.3.7 Evaluation of New ADC Technologies 33
3.4 Predictive Safety Tools for Large Molecules 33
  3.4.1 Immunogenicity 33
  3.4.2 Specialized Assays for Detection of ADCC, CDC, and ADCP 33
  3.4.3 Immunotoxicity Testing 34
  3.4.4 Predicting and Assessing Unintended Adverse Consequences 34
3.5 Strategies for Species Selection 34
3.6 Strategy for Dose-Ranging Studies for Safety Evaluation of Biopharmaceuticals 35
3.7 Conclusions 35
References 36

4 Discovery and Development Strategies for Small Interfering RNAs 39

Scott A. Barros and Gregory Hinkle

4.1 Background 39
  4.1.1 RNAi Molecular Mechanism 39
  4.1.2 Conjugate siRNAs for Hepatic Targets 39
4.2 Target Assessments 40
  4.2.1 Large Gene Families 40
  4.2.2 Short Transcripts 40
  4.2.3 Genes with Rapid mRNA Turnover 40
  4.2.4 Selecting among Alternate Transcript Variants 41
4.3 siRNA Design and Screening Strategies 41
  4.3.1 siRNA Design 41
  4.3.2 Chemical Modification of siRNA 42
  4.3.3 Screening of siRNA Therapeutics 42
4.4 Safety Lead Optimization of siRNA 45
  4.4.1 Immunostimulation Screening 45
  4.4.2 Toxicology Screening in Rodents 46
  4.4.3 Points to Consider for Chemically Modified Nucleotides 47
4.5 Integration of Lead Optimization Data for Candidate Selection and Development 48
4.6 Conclusions 49
References 49

PART III BASIS FOR *IN VITRO–IN VIVO* PK TRANSLATION 53

5 Physicochemistry and the Off-Target Effects of Drug Molecules 55

Dennis A. Smith

5.1 Lipohilicity, Polar Surface Area, and Lipoidal Permeability 55
5.2 Physicochemistry and Basic ADME Properties for High Lipoidal Permeability Drugs 56

5.3 Relationship between Volume of Distribution (V_d) and Target Access for Passively Distributed Drugs 58
5.4 Basicity, Lipophilicity, and Volume of Distribution as a Predictor of Toxicity (T): Adding The T to ADMET 59
5.5 Basicity and Lipophilicity as a Predictor of Toxicity (T): Separating the D from T in ADMET 60
5.6 Lipophilicity and PSA as a Predictor of Toxicity (T): Adding the T to ADMET 60
5.7 Metabolism and Physicochemical Properties 61
5.8 Concentration of Compounds by Transporters 61
5.9 Inhibition of Excretion Pumps 63
5.10 Conclusions 64
References 65

6 The Need for Human Exposure Projection in the Interpretation of Preclinical *In Vitro* and *In Vivo* ADME Tox Data 67
Patrick Poulin

6.1 Introduction 67
6.2 Methodology Used for Human PK Projection in Drug Discovery 67
  6.2.1 Prediction of Plasma Concentration–Time Profile by Using the Wajima Allometric Method 68
  6.2.2 Prediction of Plasma and Tissue Concentration–Time Profiles by Using the PBPK Modeling Approach 68
  6.2.3 Integrative Approaches of Toxicity Prediction Based on the Extent of Target Tissue Distribution 70
6.3 Summary of the Take-Home Messages from the Pharmaceutical Research and Manufacturers of America CPCDC Initiative on Predictive Models of Human PK from 2011 72
  6.3.1 PhRMA Initiative on the Prediction of CL 75
  6.3.2 PhRMA Initiative on the Prediction of Volume of Distribution 75
  6.3.3 PhRMA Initiative on the Prediction of Concentration–Time Profile 75
  6.3.4 Lead Commentaries on the PhRMA Initiative 76
References 77

7 ADME Properties Leading to Toxicity 82
Katya Tsaioun

7.1 Introduction 82
7.2 The Science of ADME 83
7.3 The ADME Optimization Strategy 83
7.4 Conclusions and Future Directions 89
References 90

PART IV PREDICTING ORGAN TOXICITY 93

8 Liver 95
J. Gerry Kenna, Mikael Persson, Scott Q. Siler, Ke Yu, Chuchu Hu, Minjun Chen, Joshua Xu, Weida Tong, Yvonne Will and Michael D. Aleo

8.1 Introduction 95
8.2 DILI Mechanisms and Susceptibility 96
8.3 Common Mechanisms that Contribute to DILI 98
  8.3.1 Mitochondrial Injury 98
  8.3.2 Reactive Metabolite-Mediated Toxicity 100
  8.3.3 BSEP Inhibition 102
  8.3.4 Complicity between Dual Inhibitors of BSEP and Mitochondrial Function 105
8.4 Models Systems Used to Study DILI 108

8.4.1 High Content Image Analysis 108
8.4.2 Complex Cell Models 110
8.4.3 Zebrafish 111
8.5 *In Silico* Models 114
8.6 Systems Pharmacology and DILI 118
8.7 Summary 119
References 121

9 Cardiac 130

David J. Gallacher, Gary Gintant, Najah Abi-Gerges, Mark R. Davies, Hua Rong Lu, Kimberley M. Hoagland, Georg Rast, Brian D. Guth, Hugo M. Vargas and Robert L. Hamlin

9.1 General Introduction 130
9.2 Classical *In Vitro/Ex Vivo* Assessment of Cardiac Electrophysiologic Effects 133
9.2.1 Introduction 133
9.2.2 Subcellular Techniques 134
9.2.3 Ionic Currents 134
9.2.4 AP/Repolarization Assays 135
9.2.5 Proarrhythmia Assays 136
9.2.6 Future Directions: Stem Cell-Derived CMs 136
9.2.7 Conclusions 136
9.3 Cardiac Ion Channels and *In Silico* Prediction 137
9.3.1 Introduction 137
9.3.2 High-Throughput Cardiac Ion Channel Data 137
9.3.2 *In Silico* Approaches 137
9.4 From Animal *Ex Vivo/In Vitro* Models to Human Stem Cell-Derived CMs for Cardiac Safety Testing 140
9.4.1 Introduction 140
9.4.2 Currently Available Technologies 140
9.4.3 Conclusions 141
9.5 *In Vivo* Telemetry Capabilities and Preclinical Drug Development 141
9.5.1 Introduction 141
9.5.2 CV SP Evaluations Using Telemetry 142
9.5.3 Evaluation of Respiratory Function Using Telemetry 143
9.5.4 Evaluation of CNS Using Telemetry 143
9.5.5 Evaluation of Other Systems Using Telemetry 143
9.6 Assessment of Myocardial Contractility in Preclinical Models 144
9.6.1 Introduction 144
9.6.2 Gold Standard Approaches 144
9.6.3 *In Vitro* and *Ex Vivo* Assays 145
9.6.4 *In Vivo* Assays 145
9.6.5 Translation to Clinic 146
9.7 Assessment of Large Versus Small Molecules in CV SP 147
9.7.1 Introduction 147
9.7.2 CV SP Evaluation 147
9.8 Patients do not Necessarily Respond to Drugs and Devices as do Genetically Identical, Young Mature, Healthy Mice! 148
9.8.1 Conclusions 152
References 152

10 Predictive *In Vitro* Models for Assessment of Nephrotoxicity and Drug–Drug Interactions *In Vitro* 160

Lawrence H. Lash

10.1 Introduction 160
10.1.1 Considerations for Studying the Kidneys as a Target Organ for Drugs and Toxic Chemicals 160

10.1.2 Advantages and Limitations of *In Vitro* Models in General for Mechanistic Toxicology and Screening of Potential Adverse Effects 161
10.1.3 Types of *In Vitro* Models Available for Studying Human Kidneys 162
10.2 Biological Processes and Toxic Responses of the Kidneys that are Normally Measured in Toxicology Research and Drug Development Studies 163
10.3 Primary Cultures of hPT Cells 164
10.3.1 Methods for hPT Cell Isolation 164
10.3.2 Validation of hPT Primary Cell Cultures 165
10.3.3 Advantages and Limitations of hPT Primary Cell Cultures 165
10.3.4 Genetic Polymorphisms and Interindividual Susceptibility 166
10.4 Toxicology Studies in hPT Primary Cell Cultures 166
10.5 Critical Studies for Drug Discovery in hPT Primary Cell Cultures 168
10.5.1 Phase I and Phase II Drug Metabolism 168
10.5.2 Membrane Transport 168
10.6 Summary and Conclusions 168
10.6.1 Advantages and Limitations of Performing Studies in hPT Primary Cell Cultures 168
10.6.2 Future Directions 169
References 170

11 Predicting Organ Toxicity *In Vitro*: Bone Marrow 172
Ivan Rich and Andrew J. Olaharski

11.1 Introduction 172
11.2 Biology of the Hematopoietic System 172
11.3 Hemotoxicity 173
11.4 Measuring Hemotoxicity 173
11.4.1 Uses of the CFC Assay 173
11.4.2 *In Vitro/In Vivo* Concordance 175
11.4.3 Limitations of the CFC Assay 175
11.5 The Next Generation of Assays 175
11.6 Proliferation or Differentiation? 175
11.7 Measuring and Predicting Hemotoxicity *In Vitro* 176
11.8 Detecting Stem and Progenitor Cell Downstream Events 177
11.9 Bone Marrow Toxicity Testing During Drug Development 177
11.10 Paradigm for *In Vitro* Hemotoxicity Testing 178
11.11 Predicting Starting Doses for Animal and Human Clinical Trials 179
11.12 Future Trends 179
11.13 Conclusions 180
References 180

12 Predicting Organ Toxicity *In Vitro*: Dermal Toxicity 182
Patrick J. Hayden, Michael Bachelor, Mitchell Klausner and Helena Kandárová

12.1 Introduction 182
12.2 Overview of Drug-Induced Adverse Cutaneous Reactions 182
12.3 Overview of *In Vitro* Skin Models with Relevance to Preclinical Drug Development 183
12.4 Specific Applications of *In Vitro* Skin Models and Predictive *In Vitro* Assays Relevant to Pharmaceutical Development 184
12.4.1 Skin Sensitization 184
12.4.2 Phototoxicity 185
12.4.3 Skin Irritation 187
12.5 Mechanism-Based Cutaneous Adverse Effects 187
12.5.1 Percutaneous Absorption 187

12.5.2 Genotoxicity 188
12.5.3 Skin Lightening/Melanogenesis 188
12.6 Summary 188
References 189

13 *In Vitro* Methods in Immunotoxicity Assessment 193
Xu Zhu and Ellen Evans

13.1 Introduction and Perspectives on *In Vitro* Immunotoxicity Screening 193
13.2 Overview of the Immune System 194
13.3 Examples of *In Vitro* Approaches 196
13.3.1 Acquired Immune Responses 196
13.3.2 Fcγ Receptor and Complement Binding 196
13.3.3 Assessment of Hypersensitivity 196
13.3.4 Immunogenicity of Biologics 198
13.3.5 Immunotoxicity Due to Myelotoxicity 198
13.4 Conclusions 198
References 199

14 Strategies and Assays for Minimizing Risk of Ocular Toxicity during Early Development of Systemically Administered Drugs 201
Chris J. Somps, Paul Butler, Jay H. Fortner, Keri E. Cannon and Wenhu Huang

14.1 Introduction 201
14.2 *In Silico* and *In Vitro* Tools and Strategies 201
14.3 Higher-Throughput *In Vivo* Tools and Strategies 202
14.3.1 Ocular Reflexes and Associated Behaviors 202
14.3.2 Noninvasive Ophthalmic Examinations 206
14.4 Strategies, Gaps, and Emerging Technologies 208
14.4.1 Strategic Deployment of *In Silico, In Vitro,* and *In Vivo* Tools 208
14.4.2 Emerging Biomarkers of Retinal Toxicity 210
14.5 Summary 210
References 210

15 Predicting Organ Toxicity *In Vivo*—Central Nervous System 214
Greet Teuns and Alison Easter

15.1 Introduction 214
15.2 Models for Assessment of CNS ADRs 214
15.2.1 *In Vivo* Behavioral Batteries 214
15.2.2 *In Vitro* Models 215
15.3 Seizure Liability Testing 216
15.3.1 Introduction 216
15.3.2 Medium/High Throughput Approaches to Assess Seizure Liability of Drug Candidates 216
15.3.3 *In Vivo* Approaches to Assess Seizure Liability of Drug Candidates 217
15.4 Drug Abuse Liability Testing 218
15.4.1 Introduction 218
15.4.2 Preclinical Models to Test Abuse Potential of CNS-Active Drug Candidates 219
15.5 General Conclusions 222
15.5.1 *In Vitro* 222
15.5.2 *In Vivo* 223
References 223

16 Biomarkers, Cell Models, and *In Vitro* Assays for Gastrointestinal Toxicology 227
Allison Vitsky and Gina M. Yanochko

16.1 Introduction 227
16.2 Anatomic and Physiologic Considerations 228
  16.2.1 Oral Cavity 228
  16.2.2 Esophagus 228
  16.2.3 Stomach 228
  16.2.4 Small and Large Intestine 229
16.3 GI Biomarkers 229
  16.3.1 Biomarkers of Epithelial Mass, Intestinal Function, or Cellular Damage 229
  16.3.2 Biomarkers of Inflammation 230
16.4 Cell Models of the GI Tract 231
  16.4.1 Cell Lines and Primary Cells 231
  16.4.2 Induced Pluripotent Stem Cells 232
  16.4.3 Coculture Systems 232
  16.4.4 3D Organoid Models 233
  16.4.5 Organs-on-a-Chip 235
16.5 Cell-Based *In Vitro* Assays for Screening and Mechanistic Investigations to GI Toxicity 235
  16.5.1 Cell Viability 236
  16.5.2 Cell Migration 236
  16.5.3 Barrier Integrity 236
16.6 Summary/Conclusions/Challenges 236
References 236

17 Preclinical Safety Assessment of Drug Candidate-Induced Pancreatic Toxicity: From an Applied Perspective 242
Karrie A. Brenneman, Shashi K. Ramaiah and Lauren M. Gauthier

17.1 Drug-Induced Pancreatic Toxicity 242
  17.1.1 Introduction 242
  17.1.2 Drug-Induced Pancreatic Exocrine Toxicity in Humans: Pancreatitis 243
  17.1.3 Mechanisms of Drug-Induced Pancreatic Toxicity 244
17.2 Preclinical Evaluation of Pancreatic Toxicity 245
  17.2.1 Introduction 245
  17.2.2 Risk Management and Understanding the Potential for Clinical Translation 245
  17.2.3 Interspecies and Interstrain Differences in Susceptibility to Pancreatic Toxicity 246
17.3 Preclinical Pancreatic Toxicity Assessment: *In Vivo* 247
  17.3.1 Routine Assessment 247
  17.3.2 Specialized Techniques 248
17.4 Pancreatic Biomarkers 249
  17.4.1 Introduction 249
  17.4.2 Exocrine Injury Biomarkers in Humans and Preclinical Species 250
  17.4.3 Endocrine/Islet Functional Biomarkers for Humans and Preclinical Species 252
  17.4.4 A Note on Biomarkers of Vascular Injury Relevant to the Pancreas 253
  17.4.5 Author's Opinion on the Strategy for Investments to Address Pancreatic Biomarker Gaps 253

17.5 Preclinical Pancreatic Toxicity Assessment: *In Vitro* 253
  17.5.1 Introduction to Pancreatic Cell Culture 253
  17.5.2 Modeling *In Vitro* Toxicity *In Vitro*, Testing Translatability, and *In Vitro* Screening Tools 254
  17.5.3 Case Study 1: Drug Candidate-Induced Direct Acinar Cell Toxicity *In Vivo* with Confirmation of Toxicity and Drug Candidate Screening *In Vitro* 255
  17.5.4 Case Study 2: Drug Candidate-Induced Microvascular Injury at the Exocrine–Endocrine Interface in the Rat with Unsuccessful Confirmation of Toxicity *In Vitro* and No Pancreas-Specific Monitorable Biomarkers Identified 256
  17.5.5 Emerging Technologies/Gaps: Organotypic Models 256
17.6 Summary and Conclusions 257
Acknowledgments 258
References 258

PART V ADDRESSING THE FALSE NEGATIVE SPACE—INCREASING PREDICTIVITY 261

18 Animal Models of Disease for Future Toxicity Predictions 263
Sherry J. Morgan and Chandikumar S. Elangbam

18.1 Introduction 263
18.2 Hepatic Disease Models 264
  18.2.1 Hepatic Toxicity: Relevance to Drug Attrition 264
  18.2.2 Hepatic Toxicity: Reasons for Poor Translation from Animal to Human 264
  18.2.3 Available Hepatic Models to Predict Hepatic Toxicity or Understand Molecular Mechanisms of Toxicity: Advantages and Limitations 264
18.3 Cardiovascular Disease Models 268
  18.3.1 Cardiac Toxicity: Relevance to Drug Attrition 268
  18.3.2 Cardiac Toxicity: Reasons for Poor Translation from Animal to Human 268
  18.3.3 Available CV Models to Predict Cardiac Toxicity or Understand Molecular Mechanisms of Toxicity: Advantages and Limitations 269
18.4 Nervous System Disease Models 270
  18.4.1 Nervous System Toxicity: Relevance to Drug Attrition 270
  18.4.2 Nervous System Toxicity: Reasons for Poor Translation from Animal to Human 270
  18.4.3 Available Nervous System Models to Predict Nervous System Toxicity or Understand Molecular Mechanisms of Toxicity: Advantages and Limitations 270
18.5 Gastrointestinal Injury Models 273
  18.5.1 Gastrointestinal (GI) Toxicity: Relevance to Drug Attrition 273
  18.5.2 Gastrointestinal Toxicity: Reasons for Poor Translation from Animal to Human 273
  18.5.3 Available Gastrointestinal Animal Models to Predict Gastrointestinal Toxicity or Understand Molecular Mechanisms of Toxicity: Advantages and Limitations 274
18.6 Renal Injury Models 279
  18.6.1 Renal Toxicity: Relevance to Drug Attrition 279
  18.6.2 Renal Toxicity: Reasons for Poor Translation from Animal to Human 279

18.6.3 Available Renal Models to Predict Renal Toxicity or Understand Molecular Mechanisms of Toxicity: Advantages and Limitations 280
18.7 Respiratory Disease Models 282
18.7.1 Respiratory Toxicity: Relevance to Drug Attrition 282
18.7.2 Respiratory Toxicity: Reasons for Adequate Translation from Animal to Human 282
18.7.3 Available Respiratory Models to Predict Respiratory Toxicity or Understand Molecular Mechanisms of Toxicity: Advantages and Limitations 282
18.8 Conclusion 285
References 287

19 The Use of Genetically Modified Animals in Discovery Toxicology 298
Dolores Diaz and Jonathan M. Maher

19.1 Introduction 298
19.2 Large-Scale Gene Targeting and Phenotyping Efforts 299
19.3 Use of Genetically Modified Animal Models in Discovery Toxicology 300
19.4 The Use of Genetically Modified Animals in Pharmacokinetic and Metabolism Studies 303
19.4.1 Drug Metabolism 303
19.4.2 Drug Transporters 306
19.4.3 Nuclear Receptors and Coordinate Induction 307
19.4.4 Humanized Liver Models 308
19.5 Conclusions 309
References 309

20 Mouse Population-Based Toxicology for Personalized Medicine and Improved Safety Prediction 314
Alison H. Harrill

20.1 Introduction 314
20.2 Pharmacogenetics and Population Variability 314
20.3 Rodent Populations Enable a Population-Based Approaches to Toxicology 316
20.3.1 Mouse Diversity Panel 317
20.3.2 CC Mice 318
20.3.3 DO Mice 319
20.4 Applications for Pharmaceutical Safety Science 320
20.4.1 Personalized Medicine: Development of Companion Diagnostics 320
20.4.2 Biomarkers of Sensitivity 320
20.4.3 Mode of Action 322
20.5 Study Design Considerations for Genomic Mapping 322
20.5.1 Dose Selection 322
20.5.2 Model Selection 322
20.5.3 Sample Size 323
20.5.4 Phenotyping 324
20.5.5 Genome-Wide Association Analysis 324
20.5.6 Candidate Gene Analysis 324
20.5.7 Cost Considerations 325
20.5.8 Health Status 325
20.6 Summary 326
References 326

PART VI STEM CELLS IN TOXICOLOGY **331**

21 Application of Pluripotent Stem Cells in Drug-Induced Liver Injury Safety Assessment **333**

Christopher S. Pridgeon, Fang Zhang, James A. Heslop, Charlotte M.L. Nugues, Neil R. Kitteringham, B. Kevin Park and Christopher E.P. Goldring

21.1 The Liver, Hepatocytes, and Drug-Induced Liver Injury 333
21.2 Current Models of DILI 334
  21.2.1 Primary Human Hepatocytes 334
  21.2.2 Murine Models 336
  21.2.3 Cell Lines 336
  21.2.4 Stem Cell Models 337
21.3 Uses of iPSC HLCs 338
21.4 Challenges of Using iPSCs and New Directions for Improvement 339
  21.4.1 Complex Culture Systems 340
  21.4.2 Coculture 340
  21.4.3 3D Culture 340
  21.4.4 Perfusion Bioreactors 341
21.5 Alternate Uses of HLCs in Toxicity Assessment 341
References 342

22 Human Pluripotent Stem Cell-Derived Cardiomyocytes: A New Paradigm in Predictive Pharmacology and Toxicology **346**

Praveen Shukla, Priyanka Garg and Joseph C. Wu

22.1 Introduction 346
22.2 Advent of hPSCs: Reprogramming and Cardiac Differentiation 347
  22.2.1 Reprogramming 347
  22.2.2 Cardiac Differentiation 347
22.3 iPSC-Based Disease Modeling and Drug Testing 349
22.4 Traditional Target-Centric Drug Discovery Paradigm 354
22.5 iPSC-Based Drug Discovery Paradigm 354
  22.5.1 Target Identification and Validation: “Clinical Trial in a Dish” 356
  22.5.2 Safety Pharmacology and Toxicological Testing 356
22.6 Limitations and Challenges 358
22.7 Conclusions and Future Perspective 359
Acknowledgments 360
References 360

23 Stem Cell-Derived Renal Cells and Predictive Renal *In Vitro* Models **365**

Jacqueline Kai Chin Chuah, Yue Ning Lam, Peng Huang and Daniele Zink

23.1 Introduction 365
23.2 Protocols for the Differentiation of Pluripotent Stem Cells into Cells of the Renal Lineage 367
  23.2.1 Earlier Protocols and the Recent Race 367
  23.2.2 Protocols Designed to Mimic Embryonic Kidney Development 369
  23.2.3 Rapid and Efficient Methods for the Generation of Proximal Tubular-Like Cells 372
23.3 Renal *In Vitro* Models for Drug Safety Screening 376
  23.3.1 Microfluidic and 3D Models and Other Models that have been Tested with Lower Numbers of Compounds 376
  23.3.2 *In Vitro* Models that have been Tested with Higher Numbers of Compounds and the First Predictive Renal *In Vitro* Model 376
  23.3.3 Stem Cell-Based Predictive Models 377

23.4 Achievements and Future Directions 378
Acknowledgments 379
Notes 379
References 379

PART VII CURRENT STATUS OF PRECLINICAL *IN VIVO* TOXICITY BIOMARKERS 385

24 Predictive Cardiac Hypertrophy Biomarkers in Nonclinical Studies 387
Steven K. Engle

24.1 Introduction to Biomarkers 387
24.2 Cardiovascular Toxicity 387
24.3 Cardiac Hypertrophy 388
24.4 Diagnosis of Cardiac Hypertrophy 389
24.5 Biomarkers of Cardiac Hypertrophy 389
24.6 Case Studies 392
24.7 Conclusion 392
References 393

25 Vascular Injury Biomarkers 397
Tanja S. Zabka and Kaïdre Bendjama

25.1 Historical Context of Drug-Induced Vascular Injury and Drug Development 397
25.2 Current State of DIVI Biomarkers 398
25.3 Current Status and Future of *In Vitro* Systems to Investigate DIVI 402
25.4 Incorporation of *In Vitro* and *In Vivo* Tools in Preclinical Drug Development 403
25.5 DIVI Case Study 403
References 403

26 Novel Translational Biomarkers of Skeletal Muscle Injury 407
Peter M. Burch and Warren E. Glaab

26.1 Introduction 407
26.2 Overview of Drug-Induced Skeletal Muscle Injury 407
26.3 Novel Biomarkers of Drug-Induced Skeletal Muscle Injury 409
  26.3.1 Skeletal Troponin I (sTnI) 409
  26.3.2 Creatine Kinase M (CKM) 409
  26.3.3 Myosin Light Chain 3 (Myl3) 409
  26.3.4 Fatty Acid-Binding Protein 3 410
  26.3.5 Parvalbumin 410
  26.3.6 Myoglobin 410
  26.3.7 MicroRNAs 410
26.4 Regulatory Endorsement 411
26.5 Gaps and Future Directions 411
26.6 Conclusions 412
References 412

27 **Translational Mechanistic Biomarkers and Models for Predicting Drug-Induced Liver Injury: Clinical to *In Vitro* Perspectives** **416**

Daniel J. Antoine

27.1 Introduction 416
27.2 Drug-Induced Toxicity and the Liver 417
27.3 Current Status of Biomarkers for the Assessment of DILI 418
27.4 Novel Investigational Biomarkers for DILI 419
  27.4.1 Glutamate Dehydrogenase 419
  27.4.2 Acylcarnitines 420
  27.4.3 High-Mobility Group Box-1 (HMGB1) 420
  27.4.4 Keratin-18 (K18) 421
  27.4.5 MicroRNA-122 (miR-122) 421
27.5 *In Vitro* Models and the Prediction of Human DILI 422
27.6 Conclusions and Future Perspectives 423
References 424

PART VIII KIDNEY INJURY BIOMARKERS **429**

28 **Assessing and Predicting Drug-Induced Kidney Injury, Functional Change, and Safety in Preclinical Studies in Rats** **431**

Yafei Chen

28.1 Introduction 431
28.2 Kidney Functional Biomarkers (Glomerular Filtration and Tubular Reabsorption) 433
  28.2.1 Traditional Functional Biomarkers 433
  28.2.2 Novel Functional Biomarkers 434
28.3 Novel Kidney Tissue Injury Biomarkers 435
  28.3.1 Urinary *N*-Acetyl-β-ᴅ-Glucosaminidase (NAG) 435
  28.3.2 Urinary Glutathione ***S***-Transferase α (α-GST) 435
  28.3.3 Urinary Renal Papillary Antigen 1 (RPA-1) 435
  28.3.4 Urinary Calbindin D28 435
28.4 Novel Biomarkers of Kidney Tissue Stress Response 436
  28.4.1 Urinary Kidney Injury Molecule-1 (KIM-1) 436
  28.4.2 Urinary Clusterin 436
  28.4.3 Urinary Neutrophil Gelatinase-Associated Lipocalin (NGAL) 436
  28.4.4 Urinary Osteopontin (OPN) 437
  28.4.5 Urinary ʟ-Type Fatty Acid-Binding Protein (ʟ-FABP) 437
  28.4.6 Urinary Interleukin-18 (IL-18) 437
28.5 Application of an Integrated Rat Platform (Automated Blood Sampling and Telemetry, ABST) for Kidney Function and Injury Assessment 437
References 439

29 **Canine Kidney Safety Protein Biomarkers** **443**

Manisha Sonee

29.1 Introduction 443
29.2 Novel Canine Renal Protein Biomarkers 443
29.3 Evaluations of Novel Canine Renal Protein Biomarker Performance 444
29.4 Conclusion 444
References 445

30 Traditional Kidney Safety Protein Biomarkers and Next-Generation Drug-Induced Kidney Injury Biomarkers in Nonhuman Primates 446
Jean-Charles Gautier and Xiaobing Zhou

30.1 Introduction 446
30.2 Evaluations of Novel NHP Renal Protein Biomarker Performance 447
30.3 New Horizons: Urinary MicroRNAs and Nephrotoxicity in NHPs 447
References 447

31 Rat Kidney MicroRNA Atlas 448
Aaron T. Smith

31.1 Introduction 448
31.2 Key Findings 448
References 449

32 MicroRNAs as Next-Generation Kidney Tubular Injury Biomarkers in Rats 450
Heidrun Ellinger-Ziegelbauer and Rounak Nassirpour

32.1 Introduction 450
32.2 Rat Tubular miRNAs 450
32.3 Conclusions 451
References 451

33 MicroRNAs as Novel Glomerular Injury Biomarkers in Rats 452
Rachel Church

33.1 Introduction 452
33.2 Rat Glomerular miRNAs 452
References 453

34 Integrating Novel Imaging Technologies to Investigate Drug-Induced Kidney Toxicity 454
Bettina Wilm and Neal C. Burton

34.1 Introduction 454
34.2 Overviews 455
34.3 Summary 456
References 456

35 *In Vitro* to *In Vivo* Relationships with Respect to Kidney Safety Biomarkers 458
Paul Jennings

35.1 Renal Cell Lines as Tools for Toxicological Investigations 458
35.2 Mechanistic Approaches and *In Vitro* to *In Vivo* Translation 459
35.3 Closing Remarks 460
References 460

36 Case Study: Fully Automated Image Analysis of Podocyte Injury Biomarker Expression in Rats 462
Jing Ying Ma

36.1 Introduction 462
36.2 Material and Methods 462
36.3 Results 463
36.4 Conclusions 465
References 465

37 Case Study: Novel Renal Biomarkers Translation to Humans 466

Deborah A. Burt

37.1 Introduction 466

37.2 Implementation of Translational Renal Biomarkers in Drug Development 466

37.3 Conclusion 467

References 467

38 Case Study: MicroRNAs as Novel Kidney Injury Biomarkers in Canines 468

Craig Fisher, Erik Koenig and Patrick Kirby

38.1 Introduction 468

38.2 Material and Methods 468

38.3 Results 468

38.4 Conclusions 470

References 470

39 Novel Testicular Injury Biomarkers 471

Hank Lin

39.1 Introduction 471

39.2 The Testis 471

39.3 Potential Biomarkers for Testicular Toxicity 472

  39.3.1 Inhibin B 472

  39.3.2 Androgen-Binding Protein 472

  39.3.3 SP22 472

  39.3.4 Emerging Novel Approaches 472

39.4 Conclusions 473

References 473

PART IX BEST PRACTICES IN BIOMARKER EVALUATIONS 475

40 Best Practices in Preclinical Biomarker Sample Collections 477

Jaqueline Tarrant

40.1 Considerations for Reducing Preanalytical Variability in Biomarker Testing 477

40.2 Biological Sample Matrix Variables 477

40.3 Collection Variables 480

40.4 Sample Processing and Storage Variables 480

References 480

41 Best Practices in Novel Biomarker Assay Fit-for-Purpose Testing 481

Karen M. Lynch

41.1 Introduction 481

41.2 Why Use a Fit-for-Purpose Assay? 481

41.3 Overview of Fit-for-Purpose Assay Method Validations 482

41.4 Assay Method Suitability in Preclinical Studies 482

41.5 Best Practices for Analytical Methods Validation 482

  41.5.1 Assay Precision 482

  41.5.2 Accuracy/Recovery 484

  41.5.3 Precision and Accuracy of the Calibration Curve 484

  41.5.4 Lower Limit of Quantification 484

  41.5.5 Upper Limit of Quantification 484

  41.5.6 Limit of Detection 485

41.5.7 Precision Assessment for Biological Samples 485
41.5.8 Dilutional Linearity and Parallelism 485
41.5.9 Quality Control 486
41.6 Species- and Gender-Specific Reference Ranges 486
41.7 Analyte Stability 487
41.8 Additional Method Performance Evaluations 487
References 487

42 Best Practices in Evaluating Novel Biomarker Fit for Purpose and Translatability 489
Amanda F. Baker

42.1 Introduction 489
42.2 Protocol Development 489
42.3 Assembling an Operations Team 489
42.4 Translatable Biomarker Use 490
42.5 Assay Selection 490
42.6 Biological Matrix Selection 490
42.7 Documentation of Patient Factors 491
42.8 Human Sample Collection Procedures 491
42.8.1 Biomarkers in Human Tissue Biopsy and Biofluid Samples 491
42.9 Choice of Collection Device 491
42.9.1 Tissue Collection Device 491
42.9.2 Plasma Collection Device 492
42.9.3 Serum Collection Device 492
42.9.4 Urine Collection Device 492
42.10 Schedule of Collections 492
42.11 Human Sample Quality Assurance 492
42.11.1 Monitoring Compliance to Sample Collection Procedures 492
42.11.2 Documenting Time and Temperature from Sample Collection to Processing 492
42.11.3 Optimal Handling and Preservation Methods 492
42.11.4 Choice of Sample Storage Tubes 493
42.11.5 Choice of Sample Labeling 493
42.11.6 Optimal Sample Storage Conditions 493
42.12 Logistics Plan 493
42.13 Database Considerations 493
42.14 Conclusive Remarks 493
References 493

43 Best Practices in Translational Biomarker Data Analysis 495
Robin Mogg and Daniel Holder

43.1 Introduction 495
43.2 Statistical Considerations for Preclinical Studies of Safety Biomarkers 496
43.3 Statistical Considerations for Exploratory Clinical Studies of Translational Safety Biomarkers 497
43.4 Statistical Considerations for Confirmatory Clinical Studies of Translational Safety Biomarkers 498
43.5 Summary 498
References 498

44 Translatable Biomarkers in Drug Development: Regulatory Acceptance and Qualification 500

John-Michael Sauer, Elizabeth G. Walker and Amy C. Porter

44.1 Safety Biomarkers 500
44.2 Qualification of Safety Biomarkers 501
44.3 Letter of Support for Safety Biomarkers 502
44.4 Critical Path Institute's Predictive Safety Testing Consortium 502
44.5 Predictive Safety Testing Consortium and its Key Collaborations 504
44.6 Advancing the Qualification Process and Defining Evidentiary Standards 505
References 506

PART X CONCLUSIONS 509

45 Toxicogenomics in Drug Discovery Toxicology: History, Methods, Case Studies, and Future Directions 511

Brandon D. Jeffy, Joseph Milano and Richard J. Brennan

45.1 A Brief History of Toxicogenomics 511
45.2 Tools and Strategies for Analyzing Toxicogenomics Data 513
45.3 Drug Discovery Toxicology Case Studies 519
  45.3.1 Case Studies: Diagnostic Toxicogenomics 520
  45.3.2 Case Studies: Predictive Toxicogenomics 521
  45.3.3 Case Studies: Mechanistic/Investigative Toxicogenomics 523
  45.3.4 Future Directions in Drug Discovery Toxicogenomics 524
References 525

46 Issue Investigation and Practices in Discovery Toxicology 530

Dolores Diaz, Dylan P. Hartley and Raymond Kemper

46.1 Introduction 530
46.2 Overview of Issue Investigation in the Discovery Space 530
46.3 Strategies to Address Toxicities in the Discovery Space 532
46.4 Cross-Functional Collaborative Model 533
46.5 Case-Studies of Issue Resolution in The Discovery Space 536
46.6 Data Inclusion in Regulatory Filings 538
References 538

ABBREVIATIONS 540

CONCLUDING REMARKS 542

INDEX 543

LIST OF CONTRIBUTORS

Najah Abi-Gerges, AnaBios Corporation, San Diego, CA, USA

Michael D. Aleo, Investigative Toxicology, Drug Safety Research and Development, Pfizer Inc., Groton, CT, USA

Daniel J. Antoine, MRC Centre for Drug Safety Science and Department of Molecular and Clinical Pharmacology, The Institute of Translational Medicine, University of Liverpool, Liverpool, UK

Michael Bachelor, MatTek Corporation, Ashland, MA, USA

Amanda F. Baker, Arizona Health Sciences Center, University of Arizona, Tucson, AZ, USA

Scott A. Barros, Investigative Toxicology, Alnylam Pharmaceuticals Inc., Cambridge, MA, USA

Kaïdre Bendjama, Transgene, Illkirch-Graffenstaden, France

Eric A.G. Blomme, AbbVie, Pharmaceutical Research & Development, North Chicago, IL, USA

Richard J. Brennan, Preclinical Safety, Sanofi SA, Waltham, MA, USA

Karrie A. Brenneman, Toxicologic Pathology, Drug Safety Research and Development, Pfizer Inc., Andover, MA, USA

Peter M. Burch, Investigative Pathology, Drug Safety Research and Development, Pfizer Inc., Groton, CT, USA

Deborah A. Burt, Biomarker Development and Translation, Drug Safety Research and Development, Pfizer Inc., Groton, CT, USA

Neal C. Burton, iThera Medical, GmbH, Munich, Germany

Nicholas Buss, Biologics Safety Assessment, MedImmune, Gaithersburg, MD, USA

Paul Butler, Global Safety Pharmacology, Drug Safety Research and Development, Pfizer Inc., La Jolla, CA, USA

Keri E. Cannon, Toxicology, Halozyme Therapeutics, Inc., San Diego, CA, USA

Minjun Chen, Division of Bioinformatics and Biostatistics, National Center for Toxicological Research, US Food and Drug Administration (NCTR/FDA), Jefferson, AZ, USA

Yafei Chen, Mechanistic & Investigative Toxicology, Discovery Sciences, Janssen Research & Development, L.L.C., San Diego, CA, USA

Jacqueline Kai Chin Chuah, Institute of Bioengineering and Nanotechnology, The Nanos, Singapore

Rachel Church, University of North Carolina Institute for Drug Safety Sciences, Chapel Hill, NC, USA

Thomas J. Colatsky, Division of Applied Regulatory Science, Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD, USA

Donna M. Dambach, Safety Assessment, Genentech Inc., South San Francisco, CA, USA

Mark R. Davies, QT-Informatics Limited, Macclesfield, England

Dolores Diaz, Discovery Toxicology, Safety Assessment, Genentech, Inc., South San Francisco, CA, USA

Alison Easter, Biogen Inc., Cambridge, MA, USA

Heidrun Ellinger-Ziegelbauer, Investigational Toxicology, GDD-GED-Toxicology, Bayer Pharma AG, Wuppertal, Germany

Chandikumar S. Elangbam, Pathophysiology, Safety Assessment, GlaxoSmithKline, Research Triangle Park, NC, USA

Steven K. Engle, Lilly Research Laboratories, Division of Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN, USA

Ellen Evans, Immunotoxicology Center of Emphasis, Drug Safety Research and Development, Pfizer Inc., Groton, CT, USA

Craig Fisher, Drug Safety Evaluation, Takeda California Inc., San Diego, CA, USA

Jay H. Fortner, Veterinary Science & Technology, Comparative Medicine, Pfizer Inc., Groton, CT, USA

David J. Gallacher, Global Safety Pharmacology, Janssen Research & Development, a division of Janssen Pharmaceutica N.V., Beerse, Belgium

Priyanka Garg, Stanford Cardiovascular Institute, Institute for Stem Cell Biology and Regenerative Medicine, Department of Medicine, Division of Cardiology, Stanford University School of Medicine, Stanford, CA, USA

Lauren M. Gauthier, Investigative Toxicology, Drug Safety Research and Development, Pfizer Inc., Andover, MA, USA

Jean-Charles Gautier, Preclinical Safety, Sanofi, Vitry-sur-Seine, France

Gary Gintant, Integrative Pharmacology, Integrated Science & Technology, AbbVie, North Chicago, IL, USA

Christopher E.P. Goldring, MRC Centre for Drug Safety Science, Department of Molecular and Clinical Pharmacology, The Institute of Translational Medicine, University of Liverpool, Liverpool, UK

Warren E. Glaab, Systems Toxicology, Investigative Laboratory Sciences, Safety Assessment, Merck Research Laboratories, West Point, PA, USA

Brian D. Guth, Drug Discovery Support, Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach (Riss), Germany; DST/NWU, Preclinical Drug Development Platform, Faculty of Health Sciences, North-West University, Potchefstroom, South Africa

Robert L. Hamlin, Department of Veterinary Medicine and School of Biomedical Engineering, The Ohio State University, Columbus, OH, USA

Alison H. Harrill, Department of Environmental and Occupational Health, Regulatory Sciences Program, The University of Arkansas for Medical Sciences, Little Rock, AR, USA

Dylan P. Hartley, Drug Metabolism and Pharmacokinetics, Array BioPharma Inc., Boulder, CO, USA

Patrick J. Hayden, MatTek Corporation, Ashland, MA, USA

James A. Heslop, MRC Centre for Drug Safety Science, Department of Molecular and Clinical Pharmacology, The Institute of Translational Medicine, University of Liverpool, Liverpool, UK

Gregory Hinkle, Bioinformatics, Alnylam Pharmaceuticals Inc., Cambridge, MA, USA

Mary Jane Hinrichs, Biologics Safety Assessment, MedImmune, Gaithersburg, MD, USA

Kimberly M. Hoagland, Integrated Discovery and Safety Pharmacology, Department of Comparative Biology and Safety Sciences, Amgen Inc., Thousand Oaks, CA, USA

Daniel Holder, Biometrics Research, Merck Research Laboratories, West Point, PA, USA

Michelle J. Horner, Comparative Biology and Safety Sciences (CBSS) – Toxicology Sciences, Amgen Inc., Thousand Oaks, CA, USA

Chuchu Hu, Division of Bioinformatics and Biostatistics, National Center for Toxicological Research, US Food and Drug Administration (NCTR/FDA), Jefferson, AZ, USA; Zhejiang Institute of Food and Drug Control, Hangzhou, China

Peng Huang, Institute of Bioengineering and Nanotechnology, The Nanos, Singapore

Wenhu Huang, General Toxicology, Drug Safety Research and Development, Pfizer Inc., La Jolla, CA, USA

Brandon D. Jeffy, Exploratory Toxicology, Celgene Corporation, San Diego, CA, USA

Paul Jennings, Division of Physiology, Department of Physiology and Medical Physics, Medical University of Innsbruck, Innsbruck, Austria

Raymond Kemper, Discovery and Investigative Toxicology, Drug Safety Evaluation, Vertex Pharmaceuticals, Boston, MA, USA

Helena Kandárová, MatTek *In Vitro* Life Science Laboratories, Bratislava, Slovak Republic

J. Gerry Kenna, Fund for the Replacement of Animals in Medical Experiments (FRAME), Nottingham, UK

Patrick Kirby, Drug Safety and Research Evaluation, Takeda Boston, Takeda Pharmaceuticals International Co., Cambridge, MA, USA

Neil R. Kitteringham, MRC Centre for Drug Safety Science, Department of Molecular and Clinical Pharmacology, The Institute of Translational Medicine, University of Liverpool, Liverpool, UK

Mitchell Klausner, MatTek Corporation, Ashland, MA, USA

Erik Koenig, Molecular Pathology, Takeda Boston, Takeda Pharmaceuticals International Co., Cambridge, MA, USA

Yue Ning Lam, Institute of Bioengineering and Nanotechnology, The Nanos, Singapore

Lawrence H. Lash, Department of Pharmacology, School of Medicine, Wayne State University, Detroit, MI, USA

Hank Lin, Drug Safety Research and Development, Pfizer Inc., Cambridge, MA, USA

Hua Rong Lu, Global Safety Pharmacology, Janssen Research & Development, a division of Janssen Pharmaceutica N.V., Beerse, Belgium

Karen M. Lynch, Safety Assessment, GlaxoSmithKline, King of Prussia, PA, USA

Jing Ying Ma, Molecular Pathology, Discovery Sciences, Janssen Research & Development, L.L.C., San Diego, CA, USA

Jonathan M. Maher, Discovery Toxicology, Safety Assessment, Genentech, Inc., South San Francisco, CA, USA

Sherry J. Morgan, Preclinical Safety, AbbVie, Inc., North Chicago, IL, USA

J. Eric McDuffie, Mechanistic & Investigative Toxicology, Discovery Sciences, Janssen Research & Development, San Diego, CA, USA

Joseph Milano, Milano Toxicology Consulting, L.L.C., Wilmington, DE, USA

Robin Mogg, Early Clinical Development Statistics, Merck Research Laboratories, Upper Gwynedd, PA, USA

Rounak Nassirpour, Biomarkers, Drug Safety Research and Development, Pfizer Inc., Andover, MA, USA

Charlotte M.L. Nugues, MRC Centre for Drug Safety Science, Department of Molecular and Clinical Pharmacology, The Institute of Translational Medicine, University of Liverpool, Liverpool, UK

Andrew J. Olaharski, Toxicology, Agios Pharmaceuticals, Cambridge, MA, USA

B. Kevin Park, MRC Centre for Drug Safety Science, Department of Molecular and Clinical Pharmacology, The Institute of Translational Medicine, University of Liverpool, Liverpool, UK

Mikael Persson, Lundbeck, Valby, Denmark; Currently at AstraZeneca, Molndal, Sweden

Amy C. Porter, Predictive Safety Testing Consortium (PSTC), Critical Path Institute (C-Path), Tucson, AZ, USA

Patrick Poulin, Associate Professor, Department of Occupational and Environmental Health, School of Public Health, IRSPUM, Université de Montréal, Montréal, Québec, Canada and Consultant, Québec city, Québec, Canada

Christopher S. Pridgeon, MRC Centre for Drug Safety Science, Department of Molecular and Clinical Pharmacology, The Institute of Translational Medicine, University of Liverpool, Liverpool, UK

Shashi K. Ramaiah, Biomarkers, Drug Safety Research and Development, Pfizer Inc., Cambridge, MA, USA

Georg Rast, Drug Discovery Support, Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach (Riss), Germany

Ivan Rich, Hemogenix, Inc., Colorado Springs, CO, USA

John-Michael Sauer, Predictive Safety Testing Consortium (PSTC), Critical Path Institute (C-Path), Tucson, AZ, USA

Praveen Shukla, Stanford Cardiovascular Institute, Institute for Stem Cell Biology and Regenerative Medicine, Department of Medicine, Division of Cardiology, Stanford University School of Medicine, Stanford, CA, USA

Scott Q. Siler, The Hamner Institute, Research Triangle Park, NC, USA

Aaron T. Smith, Investigative Toxicology, Eli Lilly and Company, Indianapolis, IN, USA

Dennis A. Smith, Independent Consultant, Canterbury, UK

Chris J. Somps, Investigative Toxicology, Drug Safety Research and Development, Pfizer Inc., Groton, CT, USA

Manisha Sonee, Mechanistic & Investigative Toxicology, Discovery Sciences, Janssen Research & Development, L.L.C., Spring House, PA, USA

Jaqueline Tarrant, Development Sciences-Safety Assessment, Genentech Inc., South San Francisco, CA, USA